NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/21/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization76.55 mln
Float298 mln
Earnings Date11/05/2026
Piotroski F-Score
2
/ 9
Weak
Beneish M-Score
-1.99
Caution advised
1-Year Forecast
1.66
Transformational upside
Relative Strength
8
/ 100
Severely lagging
Debt / Equity
-0.43
Negative equity
Dividend Yield
0.00%
No dividend
Business Description
Gossamer Bio is a San Diego-based medical company working to bring a new treatment called seralutinib to patients suffering from pulmonary arterial hypertension, a serious condition affecting the lungs and heart. Their lead drug, taken through inhalation, works by targeting specific proteins in the body that drive the disease and is currently being tested in a large Phase 3 clinical trial. The company holds a licensing agreement that gives them the rights to develop and sell this drug and related compounds. Founded in 2015, Gossamer Bio is focused entirely on turning this promising therapy into an approved treatment option for patients in need.